Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID)

NACompletedINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

October 20, 2021

Study Completion Date

December 20, 2021

Conditions
Covid19Thrombosis
Interventions
DRUG

Tinzaparin

"day subcutaneously • Follow-up phase 1 (Day 15 to day 30): The information is obtained at discharge and on day +14, + 28 on 30 days. The latter information is obtained from patients, from medical records or by telephone contact at the patient's home.~• Follow-up phase 2 (At 3 months: Information is obtained from patients, medical records, or by telephone contact at the patient's home."

Trial Locations (18)

Unknown

Complejo Hospitalario Universitario A Coruña, A Coruña

Hospital Universitario del Vinalopó, Alicante

Hospital Clínic Barcelona, Barcelona

Hospital Universitario Vall d'Hebron, Barcelona

Hospital Universitario de Burgos, Burgos

Hospital Virgen de la Luz, Cuenca

Hospital Universitari de Girona Doctor Josep Trueta, Girona

Hospital Clínico San Carlos, Madrid

Hospital de Emergencias Enfermera Isabel Zendal, Madrid

Hospital General Universitario Gregorio Marañón, Madrid

Hospital Universitario 12 Octubre, Madrid

Hospital Universitario Infanta Leonor, Madrid

Hospital Universitario Infanta Sofía, Madrid

Hospital Universitario Ramón y Cajal, Madrid

Complexo Hospitalario Universitario de Pontevedra, Pontevedra

Hospital Clínico Universitario de Valencia, Valencia

Hospital Clínico Universitario de Valladolid, Valladolid

Hospital Álvaro Cunqueiro, Vigo

All Listed Sponsors
lead

Hospital Universitario Infanta Leonor

OTHER

NCT04730856 - Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID) | Biotech Hunter | Biotech Hunter